December 8, 2025BloodOpen Access

Epigenetic reprogramming via EZH1/2 inhibition enhances T cell-mediated immunotherapies against multiple myeloma

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Inhibition of EZH1/2 enhances T cell cytotoxicity and reduces tumor growth in multiple myeloma, suggesting a new therapeutic strategy.

Inhibition of EZH1/2 resulted in enhanced tumor-suppressive effects on multiple myeloma cell lines.
Treatment with EZH1/2 inhibitors improved T cell-mediated responses, increasing cytokine production including IL-2.
Analysis utilized the RPMI-8226 cell line and an orthotopic xenograft model to assess therapeutic effects.
Results indicate that EZH1/2 inhibition reprograms tumor cells, reducing immune evasion and potentially enhancing immunotherapy effectiveness.

Pucillo et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

December 8, 2025BloodOpen Access

View Full Paper

Ask AI

Bookmark

Authors

Inhibition of EZH1/2 enhances T cell cytotoxicity and reduces tumor growth in multiple myeloma, suggesting a new therapeutic strategy.

Inhibition of EZH1/2 resulted in enhanced tumor-suppressive effects on multiple myeloma cell lines.
Treatment with EZH1/2 inhibitors improved T cell-mediated responses, increasing cytokine production including IL-2.
Analysis utilized the RPMI-8226 cell line and an orthotopic xenograft model to assess therapeutic effects.
Results indicate that EZH1/2 inhibition reprograms tumor cells, reducing immune evasion and potentially enhancing immunotherapy effectiveness.

Pucillo et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark